DuPont’s nutrition and bioscience business may be up for sale and Amsterdam’s Royal DSM may want to buy it, according to a report from Bloomberg.
Download Now: To be a profitable investor you first need to know the rules. Get Jim Cramer’s 25 Rules for Investing Special Report
The business could be valued at $25 billion, people who asked not to be identified told Bloomberg.
The specialty chemicals maker has been considering the sale or spinoff of its nutrition business, and has been in the process of selecting advisers to sort out offers for the division for some time, according to confidential sources.
In August, Bloomberg said that DuPont wanted to rid itself of the arm, and may be looking into a Reverse Morris Trust, a tax-free merger, as well.
Shares of DuPont fell 1.41% to $72.50 on Monday.
By Cherella Cox Owoyelu
Source: The Street
LinkedIn Twitter FacebookEvonik Industries AG has concluded a purchase agreement to acquire Wilshire Technologies Inc., with the transaction to be completed by the end of January. Headquartered in Princeton N.J., […]
LinkedIn Twitter FacebookChina’s petrochemical industry is on the start of a downcycle, according to Wood Mackenzie, as a supply overhang in the paraxylene (PX) market looks set to be joined […]
LinkedIn Twitter FacebookGerman specialty chemicals company Lanxess has completed the sale of its chrome chemicals business to Chinese leather chemicals producer Brother Enterprises for €80m ($89m). The deal was first […]
